![Simon Jones](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Simon Jones
Director Financiero/CFO en Karus Therapeutics Ltd. .
Cargos activos de Simon Jones
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Karus Therapeutics Ltd.
![]() Karus Therapeutics Ltd. BiotechnologyHealth Technology Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom. | Director Financiero/CFO | - | - |
OMERS Private Equity Europe Ltd. | Inversor de Capital Privado | 01/03/2010 | - |
Historial de carrera de Simon Jones
Antiguos cargos conocidos de Simon Jones.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Oxonica Ltd.
![]() Oxonica Ltd. Miscellaneous Commercial ServicesCommercial Services Oxonica Ltd. is an advanced materials business, which engages in licensing of patents related to nanomaterials. The company was founded in 1999 and is headquartered in Birmingham, the United Kingdom. | Director Financiero/CFO | 01/01/2000 | - |
Vodafone UK Ltd.
![]() Vodafone UK Ltd. Wireless TelecommunicationsCommunications Vodafone UK Ltd. provides mobile telecommunications services. Its services include information on services, pricing, roaming, and coverage. Its subscribers include corporate and individual consumers. Vodafone has launched 3G service in the 2004 and is responsible for wireless operations of Vodafone Group in UK. The company is headquartered in Newbury, UK. | Corporate Officer/Principal | - | - |
Glide Pharmaceutical Technologies Ltd.
![]() Glide Pharmaceutical Technologies Ltd. Pharmaceuticals: MajorHealth Technology Glide Pharmaceutical Technologies Ltd. developed and manufactured pharmaceutical products. The firm developed SDI, a solid dose injector system to improve compliance in patients self-administering long term therapy. Its pipeline of solid dose formulations includes octreotide, teriparatide, and anthrax and influenza vaccines. It also engaged in developing a non-invasive diagnostic technology that primarily focuses on prostate cancer, which aims to identify clinically significant disease based on a biochemical marker. The company was founded by Charles David Ogilvy Potter on 6th March, 2001 and was headquartered in Abingdon, the United Kingdom. | Director Financiero/CFO | - | 29/03/2013 |
Secretario Corporativo | 29/03/2013 | - |
Formación de Simon Jones.
University of Warwick | Undergraduate Degree |
Estadísticas
Internacional
Reino Unido | 7 |
Operativa
Director of Finance/CFO | 3 |
Corporate Secretary | 1 |
Undergraduate Degree | 1 |
Sectorial
Health Technology | 3 |
Communications | 2 |
Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 5 |
---|---|
Vodafone UK Ltd.
![]() Vodafone UK Ltd. Wireless TelecommunicationsCommunications Vodafone UK Ltd. provides mobile telecommunications services. Its services include information on services, pricing, roaming, and coverage. Its subscribers include corporate and individual consumers. Vodafone has launched 3G service in the 2004 and is responsible for wireless operations of Vodafone Group in UK. The company is headquartered in Newbury, UK. | Communications |
Oxonica Ltd.
![]() Oxonica Ltd. Miscellaneous Commercial ServicesCommercial Services Oxonica Ltd. is an advanced materials business, which engages in licensing of patents related to nanomaterials. The company was founded in 1999 and is headquartered in Birmingham, the United Kingdom. | Commercial Services |
Karus Therapeutics Ltd.
![]() Karus Therapeutics Ltd. BiotechnologyHealth Technology Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom. | Health Technology |
Glide Pharmaceutical Technologies Ltd.
![]() Glide Pharmaceutical Technologies Ltd. Pharmaceuticals: MajorHealth Technology Glide Pharmaceutical Technologies Ltd. developed and manufactured pharmaceutical products. The firm developed SDI, a solid dose injector system to improve compliance in patients self-administering long term therapy. Its pipeline of solid dose formulations includes octreotide, teriparatide, and anthrax and influenza vaccines. It also engaged in developing a non-invasive diagnostic technology that primarily focuses on prostate cancer, which aims to identify clinically significant disease based on a biochemical marker. The company was founded by Charles David Ogilvy Potter on 6th March, 2001 and was headquartered in Abingdon, the United Kingdom. | Health Technology |
OMERS Private Equity Europe Ltd. | Finance |
- Bolsa de valores
- Insiders
- Simon Jones
- Experiencia